Wexford Capital’s Cellectar Biosciences CLRB Stock Holding History

Wexford Capital’s Portfolio CLRB Stock Details CLRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,125	Closed	-$750K	–	88
2018 Q3	$750K	Buy	+1,125	New	+$1.33M	0.05%	110

Other funds holding CLRB

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Wexford Capital's CLRB Position: Q4 2018 in Review

Wexford Capital sold out of Cellectar Biosciences (CLRB) in Q4 2018, closing a stake of 1,125 shares — an estimated $750K sold.

Wexford Capital first reported a position in CLRB in Q3 2018 and held it in 1 quarter. The position peaked at $750K in Q3 2018. 11 funds tracked by Wall St. Rank hold CLRB as of Q4 2018.

Wexford Capital reported no remaining Cellectar Biosciences position as of Q4 2018 after selling out during the quarter.
Wexford Capital sold 1,125 Cellectar Biosciences shares in Q4 2018, an estimated $750K.
Wexford Capital first reported a position in Cellectar Biosciences in Q3 2018 and held it in 1 quarter.
Wexford Capital's Cellectar Biosciences position peaked at $750K in Q3 2018.
11 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q4 2018.

Based on Wexford Capital's 13F filing for Q4 2018, filed 14 Feb 2019.